View Older Stories
-
Citi Starts Gilead Sciences (GILD) at Buy
-
Midday movers: Diamondback Energy rises, Arm goes parabolic
-
Midday movers: Small cap stocks rule, Archer-Daniels-Midland falls, and more
-
Ideaya Biosciences (IDYA) Mentioned Positively at Citi, 'developing into an attractive takeout candidate'
-
Gilead Sciences (GILD) Prices $2B Notes Offering
-
Gilead Prices $2 Billion of Senior Unsecured Notes
-
Argus presents a list of high-yield stocks
-
Pre-Open Stock Movers 03/07: (BBBY) (TXMD) (OXY) Higher; (ALPN) (SQSP) (BLUE) Lower (more...)
-
FibroGen (FGEN), Pliant Therapeutics (PLRX) to Benefit from Galapagos (GLPG)/Gilead (GILD) Discontinued ISABELA Phase 3 Trials in IPF - Citi
-
Tech, healthcare mega deals boost virus-stricken M&A market
-
Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)
-
Pre-Open Stock Movers 07/10: (WIMI) (MATX) (SPAQ) Higher; (ZIOP) (FC) (WDFC) Lower (more...)
-
Wall Street jumps with financials; Gilead data offsets virus fears
-
AstraZeneca, Gilead merger doubted by Wall Street analysts
-
Gilead Sciences (GILD), Arcus Biosciences (RCUS) Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
-
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
-
Stock market gains alongside economic pain; some worry about over-optimism
-
Pre-Open Stock Movers 04/16: (RCUS) (LOVE) (BBBY) Higher; (DO) (RAD) (ATHX) Lower (more...)
-
After-Hours Stock Movers 04/15: (RCUS) (AM) (BBBY) Higher; (ATHX) (CALA) (LAKE) Lower (more...)
-
Gilead Sciences (GILD) Completes Forty Seven (FTSV) Acquisition
-
Gilead Completes Acquisition of Forty Seven, Inc.
-
Gilead (GILD) to Acquire Forty Seven (FTSV) for $4.9 Billion, $95.50/Share in Cash
-
Gilead to Acquire Forty Seven for $4.9 Billion
-
S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high
-
Europe closes higher as upbeat China data boosts German shares
-
Citi Upgrades Gilead Sciences (GILD) to Buy
-
Citi Upgrades Gilead Sciences (GILD) to Buy
-
UPDATE: Citi Downgrades Gilead Sciences (GILD) to Neutral
-
Gilead Sciences (GILD) PT Lowered to $100 at Citi
-
Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
-
Gilead Sciences (GILD) PT Raised to $105 at Citi
-
Gilead Sciences (GILD) PT Raised to $105 at Citi
-
Citi Upgrades Gilead Sciences (GILD) to Buy, 'Light is appearing at the end of this tunnel'
-
Juno Therapeutics (JUNO) Surges on Takeover Report as Wall Street Debates Potential Deal Valuation
-
Gilead Sciences (GILD) to Acquire Cell Design Labs for $567M
-
Gilead Sciences (GILD) and Kite to Acquire Cell Design Labs for up to $567M
-
Gilead Sciences and Kite to Acquire Cell Design Labs
-
Gilead Sciences to Acquire Cell Design Labs
-
Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6
-
UPDATE: GlaxoSmithKline (GSK) Said Exploring Takeover of United Therapeutics (UTHR), Gilead (GILD) Seen as Front-runner - Standard
-
Gilead (GILD) vs. Intercept (ICPT) NASH Debate to Heat-Up Later this Year - Citi
-
Citi Downgrades Gilead Sciences (GILD) to Neutral
-
UPDATE: Gilead Sciences (GILD) PT Lowered to $87 at Citi
-
Citi Thinks Gilead (GILD) "Still Appears To Be A Value Buy"
-
Wall Street extends rally in sharp New Year's rise
-
Notable Analyst Rating Changes 11/14: (SQ) (PTCT) (CLF) Upgraded; (STI) (STLD) (RARE) Downgraded
-
Complete Donald Trump Stock Impact Guide
-
Gilead Sciences to Present at Three Upcoming Investor Conferences in September
-
Cooperman's Omega Advisors 13F Shows Increased Stake in Silver Wheaton (SLW), United (UAL), Reduced Stake in Chimera (CIM) (More...)
-
Cooperman's Omega Back in Apple (AAPL), Enters PayPal (PYPL), UnitedHealth (UNH) (more...) - 13F

